Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy

Table 1 Characteristics of patients with testicular germ cell tumors at our Institution

Metric		Number of patients (n = 68)
Demographics
Mean age at orchiectomy (yr)		31 (16-53)
Mean BMI at 1st medical oncology visit, n (%)		29 (18.6-58.4)
Cigarette smoker or ex-smoker		35 (51)
Current cannabis user, n (%)		16 (23.5)
Clinicopathologic characteristics
Histology, n (%)	Seminoma	19 (28)
	Non-seminoma	49 (72)
Pathologic stage, n (%)	IA	1 (1.5)
	IB	1 (1.5)
	IS	6 (9)
	IIA	31 (45.5)
	IIB	10 (14.5)
	IIC	8 (11.5)
	III	1 (1.5)
	IIIA	2 (3)
	IIIB	4 (6)
	IIIC	4 (6)
Laterality, n (%)	Left	35 (52)
	Right	33 (48)
RPLN ≥ 3.0 cm before chemotherapy, n (%)	Yes	18 (26)
	No	50 (74)
Type of chemotherapy	BEP	58 (85.3%)
	EP	4 (5.9%)
	BEP + EP	6 (8.8%)
Cycles of chemotherapy	1	1 (1.5%)
	2	3 (4.4%)
	3	49 (72.0%)
	4	13 (19.1%)
	6	1 (1.5%)
	7	1 (1.5%)
RPLND	Yes	18 (26.5%)
	No	50 (73.5%)
Recurrence after initial chemotherapy	Yes	5 (7.4%)
	No	63 (92.6%)

BMI: Body mass index; BEP: Bleomycin, etoposide, and cisplatin; EP: Etoposide and cisplatin; RPLN: Retroperitoneal lymph node; RPLND: Retroperitoneal lymph node dissection.